Joan Montero
Joan Montero
Ramon y Cajal Senior Researcher at IBEC (Assistant Professor) / Dana-Farber Cancer Inst.
Подтвержден адрес электронной почты в домене ibecbarcelona.eu
Название
Процитировано
Процитировано
Год
Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy
J Montero, KA Sarosiek, JD DeAngelo, O Maertens, J Ryan, D Ercan, ...
Cell 160 (5), 977-989, 2015
2772015
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors
D Ercan, C Xu, M Yanagita, CS Monast, CA Pratilas, J Montero, ...
Cancer discovery 2 (10), 934-947, 2012
2742012
Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma
J Montero, A Morales, L Llacuna, JM Lluis, O Terrones, G Basanez, ...
Cancer research 68 (13), 5246-5256, 2008
2202008
The public repository of xenografts enables discovery and randomized phase II-like trials in mice
EC Townsend, MA Murakami, A Christodoulou, AL Christie, J Köster, ...
Cancer cell 29 (4), 574-586, 2016
2192016
Why do BCL-2 inhibitors work and where should we use them in the clinic?
J Montero, A Letai
Cell Death & Differentiation 25 (1), 56-64, 2018
2162018
BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response
KA Sarosiek, X Chi, JA Bachman, JJ Sims, J Montero, L Patel, A Flanagan, ...
Molecular cell 51 (6), 751-765, 2013
2032013
KPT‐330 inhibitor of CRM 1 (XPO 1)‐mediated nuclear export has selective anti‐leukaemic activity in preclinical models of T‐cell acute lymphoblastic leukaemia and acute myeloid …
J Etchin, T Sanda, MR Mansour, A Kentsis, J Montero, BT Le, AL Christie, ...
British journal of haematology 161 (1), 117-127, 2013
1642013
p53 regulates a non-apoptotic death induced by ROS
J Montero, C Dutta, D Van Bodegom, D Weinstock, A Letai
Cell Death & Differentiation 20 (11), 1465-1474, 2013
1272013
Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax
J Montero, J Stephansky, T Cai, GK Griffin, L Cabal-Hierro, K Togami, ...
Cancer discovery 7 (2), 156-164, 2017
1242017
Mitochondrial cholesterol in health and disease
C Garcia-Ruiz, M Mari, A Colell Riera, A Morales, F Caballero, J Montero, ...
Universidad de Murcia, 2009
1112009
Cholesterol and peroxidized cardiolipin in mitochondrial membrane properties, permeabilization and cell death
J Montero, M Mari, A Colell, A Morales, G Basañez, C Garcia-Ruiz, ...
Biochimica et Biophysica Acta (BBA)-Bioenergetics 1797 (6-7), 1217-1224, 2010
1072010
Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis
D Lagares, A Santos, PE Grasberger, F Liu, CK Probst, RA Rahimi, ...
Science Translational Medicine 9 (420), 2017
982017
Activity of the type II JAK2 inhibitor CHZ868 in B cell acute lymphoblastic leukemia
SC Wu, LS Li, N Kopp, J Montero, B Chapuy, A Yoda, AL Christie, H Liu, ...
Cancer cell 28 (1), 29-41, 2015
802015
iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry
J Ryan, J Montero, J Rocco, A Letai
Biological chemistry 397 (7), 671-678, 2016
762016
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice
J Etchin, J Montero, A Berezovskaya, BT Le, A Kentsis, AL Christie, ...
Leukemia 30 (1), 0-0, 2016
652016
Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response
DE Park, J Cheng, C Berrios, J Montero, M Cortés-Cros, S Ferretti, ...
Proceedings of the National Academy of Sciences 116 (3), 1027-1032, 2019
392019
The 2-oxoglutarate carrier promotes liver cancer by sustaining mitochondrial GSH despite cholesterol loading
A Baulies, J Montero, N Matías, N Insausti, O Terrones, G Basañez, ...
Redox biology 14, 164-177, 2018
392018
Dynamic BH3 profiling-poking cancer cells with a stick
J Montero, A Letai
Molecular & cellular oncology 3 (3), e1040144, 2016
312016
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance
K Togami, T Pastika, J Stephansky, M Ghandi, AL Christie, KL Jones, ...
The Journal of clinical investigation 129 (11), 5005-5019, 2019
302019
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov. 2012; 2: 934–947. doi: 10.1158/2159-8290
D Ercan, C Xu, M Yanagita, CS Monast, CA Pratilas, J Montero, ...
CD-12-0103.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 2012
292012
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20